Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Clene Inc. - Common Stock
(NQ:
CLNN
)
4.890
+0.030 (+0.62%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Clene Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Clene Inc. announces positive results from CNM-Au8 results from MS trial
February 05, 2024
Clene Inc (NASDAQ:CLNN) CEO Rob Etherington joined Steve Darling from Proactive to share news regarding the latest findings from the long-term open-label extension (LTE) of the VISIONARY-MS trial.
Via
TheNewswire.com
BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Produces ‘Significant and Very Promising Effect’ in Parkinson’s, MS Patients
February 02, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Unites Physics, Chemistry, Material Science, and Biology to Address Neurodegenerative Diseases With The Company’s Unique CNM-Au8(R) Pipeline
January 30, 2024
Via
Investor Brand Network
Researchers Propose New Way to Classify Parkinson’s Disease
January 29, 2024
Via
Investor Brand Network
Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment
January 24, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Clene Inc. (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as Long-Sought-After Multiple Sclerosis Treatment
January 22, 2024
Via
Investor Brand Network
Ancient DNA Suggests Origins of Multiple Sclerosis in EU
January 17, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Significant Positive Results from LTE VISIONARY-MS Trial
January 08, 2024
Via
Investor Brand Network
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
New Study Highlights Role of Mitochondria in Connecting Cancer to Dietary Fat
January 04, 2024
Via
Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) Phase 2 REPAIR-PD and REPAIR-MD Trials Indicate CNM-Au8(R)’s Ability to Increase Key Brain Metabolites, Supporting Advancement to Phase 3 Trials
January 02, 2024
Via
Investor Brand Network
Finnish Study Suggests Exercise Plays Smaller Role in Longevity
December 21, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces New Data from HEALEY ALS Platform Trial, Provides Update on ALS Clinical Development Meeting with FDA
December 21, 2023
Via
Investor Brand Network
Exposures
Product Safety
Nasdaq Gains 100 Points; CarMax Earnings Top Views
December 21, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.37% to 37,218.15 while the NASDAQ rose 0.73% to 14,885.76....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
FDA Refuses Neurology-Focused Clene's Accelerated Approval For Amyotrophic Lateral Sclerosis Treatment, Shares Fall
December 21, 2023
Clene Inc (NASDAQ: CLNN) provided an amyotrophic lateral sclerosis (ALS) regulatory update from its recent meeting with the FDA to discuss CNM-Au8 for ALS, presenting initial clinical and Neurofilament...
Via
Benzinga
Exposures
Product Safety
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
December 21, 2023
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
December 21, 2023
Via
Benzinga
Crude Oil Moves Lower; Micron Issues Strong Forecast
December 21, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.58% to 37,296.40 while the NASDAQ rose 0.77% to 14,891.87. The...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Dow Jumps 250 Points; US Weekly Jobless Claims Edge Higher
December 21, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining around 250 points on Thursday. Following the market opening Thursday, the Dow traded up 0.72% to 37,348.90 while the NASDAQ rose 0.96%...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
December 21, 2023
It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 19, 2023
Via
Benzinga
How Clene Inc. (NASDAQ: CLNN) CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders
December 18, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Lead Drug Candidate Featured in Peer-Reviewed Publication Describing Brain Target Engagement in Neurodegenerative Diseases
December 14, 2023
Via
Investor Brand Network
Stem Cell Therapy Shows Promise in Halting Progression of Cognitive Decline in MS Patients
December 11, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients
December 08, 2023
Via
Investor Brand Network
The 2023 Nobel Prize in Chemistry’s Spotlight on Nanotechnology Shines Light on Clene Inc. (NASDAQ: CLNN) Efforts to Develop Catalytically Active Nanoparticles
December 08, 2023
Via
Investor Brand Network
Study Suggests Parkinson’s Could Be Linked to Onset of Stroke, Heart Disease
November 29, 2023
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Capitalizing on the Promising Chemical and Therapeutic Properties of Nanocrystals to Address High Unmet Medical Needs
November 22, 2023
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports Q3 2023 Financial Results, Recent Operating Highlights for Its ALS Clinical Program
November 16, 2023
Via
Investor Brand Network
Blood Test Could Detect Worsening MS Symptoms in Patients
November 15, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.